A phage-encoded anti-CRISPR enables complete evasion of type VI-A CRISPR-Cas immunity

Science. 2020 Jul 3;369(6499):54-59. doi: 10.1126/science.abb6151. Epub 2020 May 28.

Abstract

The CRISPR RNA (crRNA)-guided nuclease Cas13 recognizes complementary viral transcripts to trigger the degradation of both host and viral RNA during the type VI CRISPR-Cas antiviral response. However, how viruses can counteract this immunity is not known. We describe a listeriaphage (ϕLS46) encoding an anti-CRISPR protein (AcrVIA1) that inactivates the type VI-A CRISPR system of Listeria seeligeri Using genetics, biochemistry, and structural biology, we found that AcrVIA1 interacts with the guide-exposed face of Cas13a, preventing access to the target RNA and the conformational changes required for nuclease activation. Unlike inhibitors of DNA-cleaving Cas nucleases, which cause limited immunosuppression and require multiple infections to bypass CRISPR defenses, a single dose of AcrVIA1 delivered by an individual virion completely dismantles type VI-A CRISPR-mediated immunity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacteriophages / genetics
  • Bacteriophages / metabolism*
  • CRISPR-Associated Proteins / metabolism*
  • CRISPR-Cas Systems*
  • Clustered Regularly Interspaced Short Palindromic Repeats
  • DNA Cleavage
  • Endonucleases / metabolism*
  • Listeria / virology*
  • RNA Stability
  • RNA, Guide, CRISPR-Cas Systems / genetics
  • RNA, Viral / metabolism
  • Viral Proteins / genetics
  • Viral Proteins / metabolism*

Substances

  • CRISPR-Associated Proteins
  • RNA, Guide, CRISPR-Cas Systems
  • RNA, Viral
  • Viral Proteins
  • Endonucleases

Supplementary concepts

  • Listeria seeligeri